Cyclerion Therapeutics Inc Total Liabilities
Cyclerion Therapeutics Inc total liabilities. Based on the latest financial reports, Cyclerion Therapeutics Inc (CYCN) has total liabilities worth $1.84 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CYCN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cyclerion Therapeutics Inc (2016–2025)
Total liabilities of Cyclerion Therapeutics Inc from 2016 to 2025. This chart illustrates how Cyclerion Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Cyclerion Therapeutics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Cyclerion Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Cyclerion Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Afentra PLC
LSE:AET
|
UK | GBX125.82 Million |
|
JPMorgan China Growth & Income PLC
LSE:JCGI
|
UK | GBX4.06 Million |
|
Laxmi Cotspin Limited
NSE:LAXMICOT
|
India | Rs531.88 Million |
|
The Income & Growth VCT
LSE:IGV
|
UK | GBX347.63K |
|
BioNexus Gene Lab Corp Common stock
NASDAQ:BGLC
|
USA | $804.97K |
|
Invion Ltd
AU:IVX
|
Australia | AU$1.24 Million |
|
Brown Advisory US Smaller Companies PLC
LSE:BASC
|
UK | GBX1.55 Million |
|
Majedie Investments
LSE:MAJE
|
UK | GBX813.00K |
Liability Composition Analysis (2016–2025)
This chart breaks down Cyclerion Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cyclerion Therapeutics Inc balance sheet assets.
Liquidity & Leverage Metrics
Cyclerion Therapeutics Inc Total Liabilities Ratios Explained
Cyclerion Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cyclerion Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cyclerion Therapeutics Inc (2016–2025)
The table below shows the annual total liabilities of Cyclerion Therapeutics Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $900.00K | +24.14% |
| 2024-12-31 | $725.00K | -65.24% |
| 2023-12-31 | $2.09 Million | -72.65% |
| 2022-12-31 | $7.63 Million | -31.20% |
| 2021-12-31 | $11.09 Million | -80.16% |
| 2020-12-31 | $55.88 Million | -37.03% |
| 2019-12-31 | $88.75 Million | +397.30% |
| 2018-12-31 | $17.85 Million | +27.14% |
| 2017-12-31 | $14.04 Million | +31.98% |
| 2016-12-31 | $10.64 Million | -- |
About Cyclerion Therapeutics Inc
As of September 8, 2026, Cyclerion Therapeutics, Inc. was acquired by Korsana Biosciences, Inc. in a reverse merger transaction. Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an oral… Read more